Form 4: GeneDx Holdings Director Emily Leproust Reports RSU Vesting and New Grant

GeneDx Holdings Corp. Director Emily M. Leproust reported the vesting and conversion of 12,924 Restricted Stock Units into Class A Common Stock, alongside the acquisition of 3,576 new RSUs.

Summary

• On June 18, 2025, Emily M. Leproust, a Director of GeneDx Holdings Corp. (WGS), reported changes in her beneficial ownership of company securities.
• Ms. Leproust acquired 12,924 shares of Class A Common Stock through the exercise of Restricted Stock Units (RSUs) at a price of $0 per share.
• Concurrently, 12,924 Restricted Stock Units were disposed of as they were converted into Class A Common Stock.
• Additionally, Ms. Leproust acquired 3,576 new Restricted Stock Units, also at a price of $0 per unit.
• Following these transactions, Ms. Leproust beneficially owns 21,276 shares of Class A Common Stock and 3,576 Restricted Stock Units.
• Each RSU represents a contingent right to receive one share of Class A Common Stock upon settlement for no consideration.
• The newly acquired RSUs are set to vest on the earlier of the next annual shareholder meeting or the first anniversary of the grant date, contingent on continued service.

Sentiment

Score: 7

Explanation: The filing indicates routine equity compensation for a director, involving both the vesting of previous grants and the issuance of new ones. This is generally a neutral to slightly positive signal as it aligns director interests with shareholders, but does not reflect operational performance or significant new investment.

Positives

• The acquisition of 12,924 shares of Class A Common Stock by a director indicates continued equity ownership and alignment of interests with shareholders.
• The grant of 3,576 new Restricted Stock Units to a director suggests ongoing commitment and incentivization for long-term performance.

Future Outlook

The vesting schedule for the newly granted Restricted Stock Units indicates a future milestone for equity conversion, contingent on the director's continued service to the company until the earlier of the next annual shareholder meeting or the first anniversary of the grant date.

Industry Context

This Form 4 filing reflects standard equity compensation practices for directors in publicly traded biotechnology or healthcare companies, where Restricted Stock Units are commonly used to align executive and director interests with long-term shareholder value.

Related Party Transactions

• The reported transactions involve equity compensation for a director, which is a common form of related party transaction designed to align management and board interests with shareholders.

Stakeholder Impact

• Shareholders: The transactions increase the director's direct ownership in the company, potentially aligning their interests more closely with long-term shareholder value. It also reflects the ongoing dilution from equity compensation plans.
• Employees: While not directly impacting employees, the use of RSUs as compensation is a standard practice that can influence overall compensation strategies within the company.

Next Steps

• The newly acquired Restricted Stock Units are expected to vest on the earlier of the next annual meeting of the Issuer's shareholders following the grant date, or the first anniversary of the grant date.

Key Dates

Recommendation

Keywords

GeneDx Holdings Corp., WGS, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Class A Common Stock, Director Compensation, Equity Grant, Stock Vesting